International Clinical Trial: PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07463248) titled 'PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy' on Feb. 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Wang Xin

Condition: Hepatocellular Carcinoma (HCC)

Intervention: Drug: Tislelizumab Combined With TKI Drug: Fecal Microbiota Transplantation

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 5, 2026

Target Sample Size: 64

Countries of Recru...